Cancer Causes & Control

, Volume 28, Issue 5, pp 487–495 | Cite as

Ovarian cancer epidemiology in the era of collaborative team science

  • Rikki A. Cannioto
  • Britton Trabert
  • Elizabeth M. Poole
  • Joellen M. SchildkrautEmail author
Original paper



Over the past decade, a number of consortia have formed to further investigate genetic associations, pathogenesis, and epidemiologic risk and prognostic factors for ovarian cancer. Here, we review the benefits that ovarian cancer consortia provide as well as challenges that have arisen. Methods for managing key challenges are also discussed.


We review the structural organization and some of the milestone epidemiologic publications of five consortia dedicated to the study of ovarian cancer, including the Ovarian Cancer Association Consortium (OCAC), the Ovarian Tumor Tissue Analysis (OTTA) Consortium, the Ovarian Cancer Cohort Consortium (OC3), the Collaborative Group on Epidemiological Studies of Ovarian Cancer (The Oxford Collaborative Group), and the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium.


As ovarian cancer is a rare and heterogeneous disease, consortia have made important contributions in the study of risk factors by improving statistical power beyond what any single study, or even a few studies, would provide. Thus, a major accomplishment of consortial research is enhanced characterization of histotype-specific risk factor associations. In addition, consortia have facilitated impressive synergy between researchers across many institutions, spawning new collaborative research. Importantly, through these efforts, many challenges have been met, including difficulties with data harmonization and analysis, laying a road map for future collaborations.


While ovarian cancer consortia have made valuable contributions to the ovarian cancer epidemiological literature over the past decade, additional efforts comprising of new, well-designed case–control studies are needed to further elucidate novel, histotype-specific risk, and prognostic factors which are not consistently available in existing studies.


Ovarian cancer Consortium Epidemiology 

Supplementary material

10552_2017_862_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 24 KB)


  1. 1.
    Burgio MR, Ioannidis JP, Kaminski BM, Derycke E, Rogers S, Khoury MJ, Seminara D (2013) Collaborative cancer epidemiology in the 21st century: the model of cancer consortia. Cancer Epidemiol Biomark Prev 22(12):2148–2160CrossRefGoogle Scholar
  2. 2.
    Hoover RN (2007) The evolution of epidemiologic research: from cottage industry to “big” science. Epidemiology 18(1):13–17CrossRefPubMedGoogle Scholar
  3. 3.
    The National Cancer Institute’s Epidemiology and Genomics Research Program-supported cancer epidemiology consortia. Accessed 15 Aug 2016
  4. 4.
    Bai H, Cao D, Yang J, Li M, Zhang Z, Shen K (2016) Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med 20(4):581–593CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Blagden SP (2015) Harnessing pandemonium: the clinical implications of tumor heterogeneity in ovarian cancer. Front Oncol 5:149CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, Berkowitz R, Mok SC, Bandera CA (2005) Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet 161(2):170–173CrossRefPubMedGoogle Scholar
  7. 7.
    Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO et al (2016) Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol 34(24):2888–2898CrossRefPubMedGoogle Scholar
  8. 8.
    Berchuck A, Schildkraut JM, Pearce CL, Chenevix-Trench G, Pharoah PD (2008) Role of genetic polymorphisms in ovarian cancer susceptibility: development of an International Ovarian Cancer Association Consortium. Adv Exp Med Biol 622:53–67CrossRefPubMedGoogle Scholar
  9. 9.
    Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncol 13(4):385–394CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH, Australian Cancer S et al (2013) Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer 20(2):251–262CrossRefPubMedGoogle Scholar
  11. 11.
    Faber MT, Kjaer SK, Dehlendorff C, Chang-Claude J, Andersen KK, Hogdall E, Webb PM, Jordan SJ, Rossing MA, Doherty JA et al (2013) Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies. Cancer Causes Control 24(5):989–1004CrossRefPubMedGoogle Scholar
  12. 12.
    Kelemen LE, Bandera EV, Terry KL, Rossing MA, Brinton LA, Doherty JA, Ness RB, Kjaer SK, Chang-Claude J, Kobel M et al (2013) Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. BMC Cancer 13:28CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, Risch H, Wu AH, Webb PM, Moysich K et al (2013) Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case–control studies. Int J Epidemiol 42(2):579–589CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, Carney ME, Weber RP, Akushevich L, Lo-Ciganic WH et al (2013) Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prevent Res (Philadelphia) 6(8):811–821CrossRefGoogle Scholar
  15. 15.
    Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ et al (2014) Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 106(2):djt431CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE, Fasching PA et al (2015) Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer 113(5):817–826CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cannioto R, LaMonte MJ, Risch HA, Hong CC, Sucheston-Campbell LE, Eng KH, Szender JB, Chang-Claude J, Schmalfeldt B, Klapdor R et al (2016) Chronic recreational physical inactivity and epithelial ovarian cancer risk: evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomark Prev 25:1124CrossRefGoogle Scholar
  18. 18.
    Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM et al (2016) Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. Br J Cancer 115(1):95–101CrossRefPubMedGoogle Scholar
  19. 19.
    Lee AW, Ness RB, Roman LD, Terry KL, Schildkraut JM, Chang-Claude J, Doherty JA, Menon U, Cramer DW, Gayther SA et al (2016) Association between menopausal estrogen-only therapy and ovarian carcinoma risk. Obstet Gynecol 127(5):828–836CrossRefPubMedGoogle Scholar
  20. 20.
    Kobel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL et al (2013) Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomark Prev 22(10):1677–1686CrossRefGoogle Scholar
  21. 21.
    Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Hogdall E, Deen S, Wentzensen N, Moysich KB et al (2013) Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14(9):853–862CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet (London. England) 385(9980):1835–1842CrossRefGoogle Scholar
  23. 23.
    Collaborative Group on Epidemiological Studies of Ovarian C (2012) Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med 9(4):e1001200.CrossRefGoogle Scholar
  24. 24.
    Collaborative Group on Epidemiological Studies of Ovarian C, Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet (London, England) 371(9609):303–314.CrossRefGoogle Scholar
  25. 25.
    Collaborative Group on Epidemiological Studies of Ovarian C, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2012) Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol 13(9):946–956CrossRefGoogle Scholar
  26. 26.
    Schildkraut JM, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Peters E, Schwartz AG, Terry P et al (2014) A multi-center population-based case–control study of ovarian cancer in African–American women: the African American Cancer Epidemiology Study (AACES). BMC Cancer 14:688CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C (1999) Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28(1):1–9CrossRefPubMedGoogle Scholar
  28. 28.
    Boffetta P, Armstrong B, Linet M, Kasten C, Cozen W, Hartge P (2007) Consortia in cancer epidemiology: lessons from InterLymph. Cancer Epidemiol Biomark Prev 16(2):197–199CrossRefGoogle Scholar
  29. 29.
    Clyde MA, Palmieri Weber R, Iversen ES, Poole EM, Doherty JA, Goodman MT, Ness RB, Risch HA, Rossing MA, Terry KL et al (2016) Risk prediction for epithelial ovarian cancer in 11 United States-based case–control studies: incorporation of epidemiologic risk factors and 17 confirmed genetic loci. Am J Epidemiol 184:555–569CrossRefGoogle Scholar
  30. 30.
    Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY et al (2010) Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42(10):880–884CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK et al (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42(10):874–879CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley J, Chen X, Spindler TJ et al (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet 47(8):888–897CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H et al (2013) GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 362–370(4):370e361–370e362Google Scholar
  34. 34.
    Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R et al (2009) A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41(9):996–1000CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ, Li Q, Marks JR, Berchuck A, Lee JM et al (2015) Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis 36(11):1341–1353CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Phelan CM KK, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan M, Chornokur G, Earp MA, Lyra PA, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D et al (2017) Identification of twelve novel susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet (in press) Google Scholar
  37. 37.
    Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet (London, England) 371(9609):303–314CrossRefGoogle Scholar
  38. 38.
    Fortier I, Doiron D, Burton P, Raina P (2011) Invited commentary: consolidating data harmonization—how to obtain quality and applicability? Am J Epidemiol 174(3):261–264 (author reply 265–266) CrossRefGoogle Scholar
  39. 39.
    Stukel TA, Demidenko E, Dykes J, Karagas MR (2001) Two-stage methods for the analysis of pooled data. Stat Med 20(14):2115–2130CrossRefPubMedGoogle Scholar
  40. 40.
    Friedenreich CM (2002) Commentary: improving pooled analyses in epidemiology. Int J Epidemiol 31(1):86–87CrossRefPubMedGoogle Scholar
  41. 41.
    Preston-Martin S, Pogoda JM, Schlehofer B, Blettner M, Howe GR, Ryan P, Menegoz F, Giles GG, Rodvall Y, Choi NW et al (1998) An international case–control study of adult glioma and meningioma: the role of head trauma. Int J Epidemiol 27(4):579–586CrossRefPubMedGoogle Scholar
  42. 42.
    Morton LM, Sampson JN, Cerhan JR, Turner JJ, Vajdic CM, Wang SS, Smedby KE, de Sanjose S, Monnereau A, Benavente Y et al (2014) Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014(48):1–14CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Boyle P (1990) SEARCH programme of the International Agency of Research on Cancer. Eur J Cancer (Oxford, England) 26(5):547–549CrossRefGoogle Scholar
  44. 44.
    Riboli E, Kaaks R (1997) The EPIC project: rationale and study design. European prospective investigation into cancer and nutrition. Int J Epidemiol 26(Suppl 1):S6–S14CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Rikki A. Cannioto
    • 1
  • Britton Trabert
    • 2
  • Elizabeth M. Poole
    • 3
  • Joellen M. Schildkraut
    • 4
    Email author
  1. 1.Department of Cancer Prevention and ControlRoswell Park Cancer InstituteBuffaloUSA
  2. 2.Division of Cancer Epidemiology and GeneticsNational Cancer InstituteBethesdaUSA
  3. 3.Channing Division of Network MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  4. 4.Department of Public Health Sciences, School of MedicineThe University of VirginiaCharlottesvilleUSA

Personalised recommendations